CMS Decision Leaves Millions Without Access to Obesity Medications The Obesity Society is deeply disappointed by the Centers for Medicare & Medicaid Services final rule continuing to exclude obesity medications from Medicare Part D and Medicaid coverage. This decision limits access to proven treatments for a chronic, complex disease that affects over 40% of U.S. adults. “This is a setback—but also a call to action for not only those who champion obesity care, but for clinicians across medicine and the patients they serve,” said TOS President Marc-Andre Cornier, MD, FTOS. ✅ TOS urges providers to diagnose obesity in the medical record and to support the Treat and Reduce Obesity Act, which would expand access to both medications and behavioral therapy for Medicare beneficiaries. 📢 We call on the entire medical community to advocate for accessible, evidence-based obesity care. 🔗 Read our full statement: https://ow.ly/FY5a50Vw5ua #ObesityCare #HealthcareAccess #CMS #GLP1 #PublicHealth #Medicare #TreatAndReduceObesityAct #TheObesitySociety
